Pediatric nephrology (Berlin, Germany) · 2025
Seroconversion following varicella vaccination in children and adolescents with nephrotic syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ponnachan Samith, Deepthi Bobbity, Dhodapkar Rahul, Ramamurthy Narayan, Krishnasamy Sudarsan, Krishnamurthy Sriram
Аннотация
BACKGROUND: Limited data exist on seroconversion rates post-varicella vaccination in children with idiopathic nephrotic syndrome (NS).
METHODS: This cross-sectional study assessed anti-varicella IgG antibodies (VZV-IgG) in idiopathic NS children aged 1-18 years who were previously vaccinated (2 doses at a minimum 8-week interval), at least 3 months prior to enrolment. Exclusion criteria included secondary NS and eGFR < 60 mL/min/1.73 m2 at the time of vaccination. Baseline characteristics and seroconversion titres (VZV-IgG ≥ 110 IU/L) by enzyme-linked immunosorbent assay (ELISA) kit were assessed.
RESULTS: Two-hundred children with idiopathic NS (55.5% males) received varicella vaccine. The median interval between doses was 3 months [IQR 2, 7], with a median age at vaccination of 6.8 years [3.8, 9.8], and a median illness duration of 4.1 years [1.7, 6.6]. Overall seroconversion rate was 64.5% with median VZV-IgG titres of 179 [IQR 62, 452] IU/L. The seroconversion was significantly associated with clinical phenotype when unadjusted for confounders. On univariate analysis, each additional relapse, children on levamisole post-vaccination, those on one second-line immunosuppressive agent, on two second-line immunosuppressive agents, and each additional month after vaccination were associated with 16%, 88%, 66%, 77%, and 3% significantly lower odds of seroconversion. The seroconversion rates or titres among those vaccinated within 4 weeks of discontinuation of steroids were however not significantly different. Breakthrough varicella occurred in 1.5%.
CONCLUSIONS: To conclude, this study demonstrates that varicella vaccination confers seroprotection in approximately two-thirds of children with NS, with low rates of breakthrough varicella.
METHODS: This cross-sectional study assessed anti-varicella IgG antibodies (VZV-IgG) in idiopathic NS children aged 1-18 years who were previously vaccinated (2 doses at a minimum 8-week interval), at least 3 months prior to enrolment. Exclusion criteria included secondary NS and eGFR < 60 mL/min/1.73 m2 at the time of vaccination. Baseline characteristics and seroconversion titres (VZV-IgG ≥ 110 IU/L) by enzyme-linked immunosorbent assay (ELISA) kit were assessed.
RESULTS: Two-hundred children with idiopathic NS (55.5% males) received varicella vaccine. The median interval between doses was 3 months [IQR 2, 7], with a median age at vaccination of 6.8 years [3.8, 9.8], and a median illness duration of 4.1 years [1.7, 6.6]. Overall seroconversion rate was 64.5% with median VZV-IgG titres of 179 [IQR 62, 452] IU/L. The seroconversion was significantly associated with clinical phenotype when unadjusted for confounders. On univariate analysis, each additional relapse, children on levamisole post-vaccination, those on one second-line immunosuppressive agent, on two second-line immunosuppressive agents, and each additional month after vaccination were associated with 16%, 88%, 66%, 77%, and 3% significantly lower odds of seroconversion. The seroconversion rates or titres among those vaccinated within 4 weeks of discontinuation of steroids were however not significantly different. Breakthrough varicella occurred in 1.5%.
CONCLUSIONS: To conclude, this study demonstrates that varicella vaccination confers seroprotection in approximately two-thirds of children with NS, with low rates of breakthrough varicella.